{"title":"在代谢功能障碍相关脂肪性肝炎和中晚期肝纤维化患者中,与安慰剂相比,西马鲁肽(每周2.4mg皮下注射)是否能改善肝脏组织学,它是否安全?]","authors":"Alexandre Mutchmore , Dusanka Grbic , Michel Cauchon , Marc-Émile Plourde , Luc Lanthier","doi":"10.1016/j.revmed.2025.08.009","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":54458,"journal":{"name":"Revue De Medecine Interne","volume":"46 10","pages":"Pages 613-614"},"PeriodicalIF":0.9000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chez les personnes atteintes de stéatohépatite associée à un dysfonctionnement métabolique (MASH) avec une fibrose hépatique modérée ou avancée, le sémaglutide à la dose de 2,4 mg sous-cutanée hebdomadaire améliore-t-il l’atteinte histologique comparativement au placebo, tout en étant sécuritaire ?\",\"authors\":\"Alexandre Mutchmore , Dusanka Grbic , Michel Cauchon , Marc-Émile Plourde , Luc Lanthier\",\"doi\":\"10.1016/j.revmed.2025.08.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":54458,\"journal\":{\"name\":\"Revue De Medecine Interne\",\"volume\":\"46 10\",\"pages\":\"Pages 613-614\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue De Medecine Interne\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0248866325007477\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue De Medecine Interne","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0248866325007477","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Chez les personnes atteintes de stéatohépatite associée à un dysfonctionnement métabolique (MASH) avec une fibrose hépatique modérée ou avancée, le sémaglutide à la dose de 2,4 mg sous-cutanée hebdomadaire améliore-t-il l’atteinte histologique comparativement au placebo, tout en étant sécuritaire ?
期刊介绍:
Official journal of the SNFMI, La revue de medecine interne is indexed in the most prestigious databases. It is the most efficient French language journal available for internal medicine specialists who want to expand their knowledge and skills beyond their own discipline. It is also the main French language international medium for French research works. The journal publishes each month editorials, original articles, review articles, short communications, etc. These articles address the fundamental and innumerable facets of internal medicine, spanning all medical specialties. Manuscripts may be submitted in French or in English.
La revue de medecine interne also includes additional issues publishing the proceedings of the two annual French meetings of internal medicine (June and December), as well as thematic issues.